Kineret — CareFirst (Caremark)

Reauthorization criteria

• Adult member using Kineret for moderately to severely active rheumatoid arthritis.
• Member achieves or maintains a positive clinical response as evidenced by disease activity improvement of at least 20% from baseline in tender joint count, swollen joint count, pain, or disability.

Approval duration

12 months